|
FR2551758B1
(fr)
*
|
1983-08-16 |
1986-01-31 |
Anvar |
Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
|
|
US4650771A
(en)
*
|
1983-11-04 |
1987-03-17 |
Miles Laboratories, Inc. |
Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
|
|
US4595656A
(en)
*
|
1984-01-06 |
1986-06-17 |
Becton Dickinson & Company |
Coupling agents and products produced therefrom
|
|
US4654311A
(en)
*
|
1984-06-15 |
1987-03-31 |
Syntex (U.S.A.) Inc. |
Serum pretreatment for digoxin assay
|
|
US4767720A
(en)
*
|
1985-08-29 |
1988-08-30 |
Hsc Research Development Corporation |
Antidigoxin antibodies
|
|
US5013720A
(en)
*
|
1986-05-06 |
1991-05-07 |
Abbott Laboratories |
SAP-6-Val proteins and methods
|
|
FR2601141A1
(fr)
*
|
1986-07-02 |
1988-01-08 |
Centre Nat Rech Scient |
Produit de couplage a base d'haptene, utile notamment comme substance immunogene, anticorps correspondants et applications
|
|
US5034317A
(en)
*
|
1987-01-30 |
1991-07-23 |
Polaroid Corporation |
Enzyme controlled release system and organic conjugate reactant
|
|
US6326136B1
(en)
*
|
1988-04-01 |
2001-12-04 |
Digene Corporation |
Macromolecular conjugate made using unsaturated aldehydes
|
|
DE3836656A1
(de)
*
|
1988-10-27 |
1990-05-03 |
Boehringer Mannheim Gmbh |
Neue digoxigenin-derivate und ihre verwendung
|
|
CA2031109C
(en)
*
|
1990-07-27 |
1992-01-28 |
Susan J. Danielson |
Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
|
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
RU2132553C1
(ru)
*
|
1996-05-30 |
1999-06-27 |
Ивановская Елена Алексеевна |
Количественное определение дигоксина в сыворотке крови методом инверсионной вольтамперометрии
|
|
WO1998036099A1
(en)
*
|
1997-02-18 |
1998-08-20 |
Oncor, Inc. |
Detection of targets with green fluorescent protein and fluorescent variants thereof
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
HK1038882A1
(zh)
*
|
1998-04-15 |
2002-04-04 |
利思进药品公司 |
通过共同给予血管生成抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
|
|
CA2372400C
(en)
*
|
1999-05-19 |
2010-04-27 |
Lexigen Pharmaceuticals Corp. |
Expression and export of interferon-alpha proteins as fc fusion proteins
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK1842002A3
(en)
*
|
1999-08-09 |
2003-09-11 |
Lexigen Pharm Corp |
A fusion protein, a multi-function protein complex, a multi-function fusion protein, a nucleic acid, a cell, their use, method for preparing a fusion protein and method of targeting cytokines
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
EP1252192B1
(en)
|
2000-02-11 |
2006-08-16 |
MERCK PATENT GmbH |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
PT1294401E
(pt)
|
2000-06-29 |
2007-11-09 |
Merck Patent Gmbh |
Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
|
|
BR0207854A
(pt)
*
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
AU2002308562B2
(en)
|
2001-05-03 |
2008-01-24 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use thereof
|
|
RU2312677C9
(ru)
|
2001-12-04 |
2008-03-27 |
Мерк Патент Гмбх |
Иммуноцитокины с модулированной селективностью
|
|
ATE492565T1
(de)
*
|
2002-01-31 |
2011-01-15 |
Randox Lab Ltd |
Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
|
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
|
RU2366664C2
(ru)
*
|
2002-12-17 |
2009-09-10 |
Мерк Патент Гмбх |
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
|
|
US7935539B2
(en)
*
|
2003-02-14 |
2011-05-03 |
Siemens Healthcare Diagnostics, Inc. |
Generic method for latex agglutination assays
|
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
JP2005172694A
(ja)
*
|
2003-12-12 |
2005-06-30 |
Fuji Photo Film Co Ltd |
タンパク質の検出方法
|
|
EP1699822B1
(en)
*
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
|
RU2370276C2
(ru)
*
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
|
US8420087B2
(en)
*
|
2004-01-05 |
2013-04-16 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
CN101072793B
(zh)
*
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
|
CA3125026C
(en)
|
2006-11-01 |
2023-04-04 |
Ventana Medical Systems, Inc. |
Haptens, hapten conjugates, compositions thereof and method for their preparation and use
|
|
US7682789B2
(en)
*
|
2007-05-04 |
2010-03-23 |
Ventana Medical Systems, Inc. |
Method for quantifying biomolecules conjugated to a nanoparticle
|
|
EP3561513A1
(en)
|
2007-05-23 |
2019-10-30 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
EP2995925B1
(en)
|
2008-06-05 |
2021-12-15 |
Ventana Medical Systems, Inc. |
Composition for histochemical processing
|
|
EP2370092A1
(en)
|
2008-12-03 |
2011-10-05 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
|
CA2759333A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
USPP22463P3
(en)
*
|
2010-02-16 |
2012-01-17 |
Menachem Bornstein |
Gypsophila plant named ‘Pearl Blossom’
|
|
CA2800936A1
(en)
|
2010-07-02 |
2012-01-05 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
BR112013014644A2
(pt)
*
|
2011-01-03 |
2017-03-07 |
F Hoffmann - La Roche Ag |
composição farmacêutica e complexo
|
|
AU2012294814A1
(en)
|
2011-08-05 |
2014-02-27 |
Research Development Foundation |
Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
|
|
WO2014066590A1
(en)
|
2012-10-24 |
2014-05-01 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
|
CN106659909B
(zh)
|
2013-08-21 |
2022-01-11 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
|
MX2018004838A
(es)
|
2015-11-06 |
2019-07-18 |
Ventana Med Syst Inc |
Diagnosticos representativos.
|
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
|
ES2883297T3
(es)
|
2016-03-29 |
2021-12-07 |
Stcube Inc |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
|
JP2019528251A
(ja)
|
2016-07-20 |
2019-10-10 |
エスティーキューブ,インコーポレイテッド |
グリコシル化pd−l1に結合する抗体の組合せを使用するがんの処置および治療の方法
|
|
AU2018277838C1
(en)
|
2017-05-31 |
2025-08-07 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
|
US11464784B2
(en)
|
2017-09-15 |
2022-10-11 |
The Regents Of The University Of California |
Inhibition of aminocylase 3 (AA3) in the treatment of cancer
|
|
US20200290978A1
(en)
|
2017-09-26 |
2020-09-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
US11691141B2
(en)
|
2017-11-13 |
2023-07-04 |
Roche Sequencing Solutions, Inc. |
Devices for sample analysis using epitachophoresis
|
|
WO2020058339A1
(en)
*
|
2018-09-20 |
2020-03-26 |
Ventana Medical Systems, Inc. |
Coumarin-based crosslinking reagents
|
|
WO2020074742A1
(en)
|
2018-10-12 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
Detection methods for epitachophoresis workflow automation
|
|
CN110174363A
(zh)
*
|
2019-01-09 |
2019-08-27 |
北京九强生物技术股份有限公司 |
6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
|
|
CN114269916A
(zh)
|
2019-05-14 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用于样品分析的装置和方法
|
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
CN113736744B
(zh)
*
|
2021-10-14 |
2023-07-18 |
江南大学 |
洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用
|